Author/Authors :
Dulce M. Garrido، نويسنده , , David F. Corbett، نويسنده , , Kate A. Dwornik، نويسنده , , Aaron S. Goetz، نويسنده , , Thomas R. Littleton، نويسنده , , Steve C. McKeown، نويسنده , , Wendy Y. Mills، نويسنده , , Terrence L. Smalley Jr.، نويسنده , , Celia P. Briscoe، نويسنده , , Andrew J. Peat، نويسنده ,
Abstract :
The first report on the identification and structure–activity relationships of a novel series of GPR40 agonists based on a 3-(4-{[N-alkyl]amino}phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC50s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes.
Keywords :
GPR40 agonists , Fatty acid receptor , type 2 diabetes , GPR40 , GPCR agonist , G-protein coupled receptor agonist , asymmetric cyclopropanation